• Most Popular
  • Most Shared

UPDATE 1-EU approves Actelion's Tracleer for children

Mon Jul 6, 2009 1:13am EDT

Stocks

   

* Only drug with approved paediatric formulation

* Actelion trying to expand Tracleer use

(Adds details)

ZURICH, July 6 (Reuters) - European regulators approved Actelion's (ATLN.VX) Tracleer for the treatment of heart and lung condition pulmonary arterial hypertension (PAH) in children, the Swiss biotech group said on Monday.

Tracleer is now the only drug with an approved paediatric formulation for treating children from two years of age, Actelion said in a statement.

The company is trying to expand use of Tracleer, which already rakes in more than $1 billion a year, into new diseases and patients to reduce its dependence on its main PAH market. (Reporting by Sam Cage; editing by Simon Jessop)



More from Reuters

Photo

Treasury to seek easing of bailout fund rules

WASHINGTON (Reuters) - The Treasury Department will ask Congress to ease restrictions on the use of bank bailout funds so it can use some of the money to encourage more lending to small businesses, a department official said on Wednesday.

» More Top News
Malaysians participate in computer attack and defence hacking competition during The 3rd Annual Hack-In-The-Box Security Conference 2004 in Kuala Lumpur on October 6, 2004. REUTERS/Bazuki Muhammad
Commentary:

Year of the breach

Data security breaches are nasty business and should be avoided at all costs, writes Kevin Prince, a chief technology officer at Perimeter e-Security. Here's a look at the biggest breaches and blunders of 2009.  Commentary 

Technology
Cannabis sativa plant is seen in Buenos Aires, August 21, 2009. REUTERS/Enrique Marcarian
Commentary:

Obama, drugs, common sense

American attitudes towards drug prohibition – and above all, punitive laws on marijuana – are changing too fast for policymakers and legislators to ignore, writes columnist Bernd Debusmann.  Commentary 

U.S.